Published in JAMA · View the paper (DOI)
The study found that glucagon-like peptide-1 agonists are associated with a higher risk of pancreatitis, gastroparesis, and bowel obstruction compared to bupropion-naltrexone. Patients considering weight loss medication should be aware of these potential risks due to the drugs' wide use.
Coverage from 2 institutions